-
公开(公告)号：US20250015731A1
公开(公告)日：2025-01-09
申请号：US18893552
申请日：2024-09-23
Inventor： Mohammed Jasim Uddin , Abu Musa Abdullah , Alejandro Flores
IPC: H02N1/04 , H04B1/3888
Abstract: A power and/or electricity generating source and/or component that is TENG-based, and that may be configured as an assembly and/or component for powering one or more electronic devices, is disclosed, a case, carrier or other carrying container, for example a case for a cell phone, ipad, electronic tablet, personal computer, or any similar device, that provides an electricity source to power the cell phone, ipad, electronic tablet, is disclosed. The energy generating carriers and/or containers and configurations thereof, also provide an electricity energy storage source, such as a capacitor. This electronic energy storage source may be incorporated within an electronic device itself, or may be incorporated within the case and/or covering. A bridge rectifier is also provided in some embodiments of the case. Upon walking or touching a surface of an electronic device, the power generating source will harness mechanical energy, and provide for the generation of electricity with the one or more TENG components (TESTEC) that comprise the energy generating unit. Metal particles (silver, copper, etc. nanoparticles) incorporated within and/or on polymeric layers and/or a film of the carrier and/or container assembly, are also provided, and provide for enhanced energy generating capacity of the energy generating and storage components described.
-
2.发明申请公开(公告)号：US20240424013A1
公开(公告)日：2024-12-26
申请号：US18829162
申请日：2024-09-09
Inventor： Jerry SHAY , Yang-Xin FU , Ilgen MENDER , Anli ZHANG
IPC: A61K31/7076 , A61N5/00 , A61P35/00 , C07K16/28
Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2′-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.
-
公开(公告)号：US20240401007A1
公开(公告)日：2024-12-05
申请号：US18811649
申请日：2024-08-21
Inventor： John W. Schoggins , Wenchun Fan , Daniel J. Siegwart , Qiang Cheng
Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.
-
公开(公告)号：US20240394872A1
公开(公告)日：2024-11-28
申请号：US18645146
申请日：2024-04-24
Inventor： Darin T. OKUDA , Dinesh K. SIVAKOLUNDU
Abstract: The present disclosure includes methods, apparatuses, and systems for three-dimensional phenotyping and physiologic characterization of brain lesions and tissue encompassing one or more enlarged boundaries surrounding the brain lesion to study the metabolic and physiologic profiles from tissue within and around lesions and their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen-level-dependant (BOLD) slope was used to metabolically characterize lesions. Metabolically active lesions with more intact tissue and myelin architecture have more symmetrical shapes and more complex surface textures compared to metabolically inactive lesions with less intact tissue and myelin architecture. The association of lesions' shapes and surface features with their metabolic signatures aid in the translation of MRI data to clinical management by providing information related to metabolic activity, lesion age, and risk for disease reactivation and self-repair.
-
公开(公告)号：US12152071B2
公开(公告)日：2024-11-26
申请号：US17096280
申请日：2020-11-12
Inventor： Ningyan Zhang , Zhiqiang An , Anil K. Sood
IPC: C07K16/22 , A61K9/00 , A61K39/00 , A61P35/00 , C12N15/113 , G01N33/574
Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
Patent Agency Ranking
公开(公告)号：US20240376222A1
公开(公告)日：2024-11-14
申请号：US18691125
申请日：2022-09-13
Inventor： Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
IPC: C07K16/28 , A61K49/00 , C07K14/725
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TfR protein, e.g., a mammalian TfR or human TfR, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20240342314A1
公开(公告)日：2024-10-17
申请号：US18683101
申请日：2022-09-29
Inventor： Rachel M BAILEY
IPC: A61K48/00 , A61P25/28 , C07K14/705 , C12N15/86
CPC classification number: A61K48/0058 , A61K48/0075 , A61P25/28 , C07K14/705 , C12N15/86 , C12N2750/14143 , C12N2750/14145 , C12N2830/50
Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC13A5 loss, misfunction and/or deficiency, including neurological disorders, diseases, and conditions such as epileptic encephalopathy. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for an SLC13A5 polypeptide.
-
公开(公告)号：US20240327411A1
公开(公告)日：2024-10-03
申请号：US18471912
申请日：2023-09-21
Inventor： Jia Zhou , Wenbo Zhang , Hua Liu
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D498/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D498/04 , C07D519/00
Abstract: The present invention relates to novel small molecule activators of Sirt6, for example, compounds of the general Formula (I), their methods and use for the treatment of various human diseases such as cancer, inflammatory diseases, neurodegenerative diseases, and infectious diseases:
-
公开(公告)号：US20240325454A1
公开(公告)日：2024-10-03
申请号：US18575499
申请日：2022-06-30
Inventor： Eric N. OLSON , Rhonda BASSEL-DUBY , Takahiko NISHIYAMA
CPC classification number: A61K35/34 , A61K48/005 , C12N9/22 , C12N15/11 , C12N15/86 , C12N2310/20 , C12N2750/14143
Abstract: Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) designed for a CRISPR/Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies. For example, provided herein are composition and methods for the correction of dilated cardiomyopathy by precise genomic editing of RBM20 mutations in human cells and mice.
-
公开(公告)号：US20240285831A1
公开(公告)日：2024-08-29
申请号：US18649976
申请日：2024-04-29
Inventor： Jonathan CHENG , Edward KEEFER , Srikanth VASUDEVAN
IPC: A61L27/54 , A61K31/5355 , A61K38/20 , A61L27/24
CPC classification number: A61L27/54 , A61K31/5355 , A61K38/204 , A61L27/24 , A61L2300/204 , A61L2300/252 , A61L2430/32
Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.
-
-
-
-
-
-
-
-
-
Search Results
1658
records
(took 0.207 seconds)
